menu

CME: Moderate-to-Severe Atopic Dermatitis: Expert Insights on Late-Breaking Data in Systemic Treatment

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Moderate-to-Severe Atopic Dermatitis: Expert Insights on Late-Breaking Data in Systemic Treatment

close
0.25 credits
15 Minutes
Moderate-to-Severe Atopic Dermatitis: Expert Insights on Late-Breaking Data in Systemic Treatment
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
Details
Presenters
Related
Comments
  • Overview

    Statment of Need
    Recent investigations into the underlying mechanisms of atopic dermatitis have revealed the importance of the JAK/STAT pathway and downstream cytokines in driving inflammatory response and AD pathogenesis and have informed the recent development of novel targeted agents. The recent and rapid emergence of new data on novel targeted treatments for moderate-to-severe AD creates a knowledge gap for dermatologists and allergists. As emerging targeted therapies have the potential to become available relatively quickly, dermatologists and allergists must be familiar with the practical considerations associated with using these agents so that they are prepared to integrate these agents into the management of patients with moderate-to-severe AD in a safe and appropriate manner. This activity will bridge the knowledge gap by providing expert perspective on the translation of these data into clinical practice to optimize patient outcomes.

  • Target Audience

    This activity is intended for dermatologists and allergy clinicians who are involved in the care and treatment of patients with moderate-to-severe AD.  

  • Learning Objectives

    Upon completion, participants should be able to: 

    • Evaluate the clinical relevance of recent trial data surrounding targeted therapies in development for the treatment of moderate-to-severe AD 
  • Faculty

    Lawrence F. Eichenfield, MD
    Professor of Dermatology and Pediatrics
    Vice Chair, Department of Dermatology
    University of California San Diego School of Medicine
    Chief, Pediatric and Adolescent Dermatology
    Rady Children's Hospital
    San Diego, CA 

    Linda Stein Gold, MD
    Director of Dermatology Clinical Research  
    Henry Ford Health System  
    Detroit, MI  
    Division Head of Dermatology  
    Henry Ford Health System  
    West Bloomfield, MI

  • Activity Planners

    Christie Avraamides, PhD
    Clinical Content Manager
    Med-IQ
    Baltimore, MD

    Samantha Gordon, MS
    Accreditation Manager
    Med-IQ
    Baltimore, MD

    Amy Sison
    Director of CME
    Med-IQ
    Baltimore, MD

  • Disclosure Policy and Statements

    Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

    Lawrence F. Eichenfield, MD 
    Consulting fees/advisory boards: Almirall, Asana, Cutanea, Dermavant, DS Biopharma, Forte, Galderma Laboratories, L.P., Glenmark, Incyte Corporation, LEO Pharma, Inc., Lilly USA, LLC, L'Oreal, MatriSys Bioscience, Medimetriks/Otsuka America Pharmaceutical, Inc., MorphoSys, Novan, Novartis Pharmaceuticals Corporation, Ortho Dermatologics/Valeant Pharmaceuticals International, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme 

    Investigator: AbbVie Inc., LEO Pharma, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme 

    Linda Stein Gold, MD  
    Consulting fees/advisory boards: AbbVie Inc., Arcutis Biotherapeutics, Incyte Corporation, LEO Pharma, Inc., Lilly USA, LLC, Pfizer, Inc. 

    Fees received for promotional/non-CME activities: Pfizer, Inc. 

    Contracted research: AbbVie Inc., Arcutis Biotherapeutics, Incyte Corporation, LEO Pharma, Inc., Lilly USA, LLC, Pfizer, Inc. 

    References to unlabeled/unapproved off-label drug uses or products are mentioned in this presentation.

    The peer reviewers and activity planners have no financial relationships to disclose.

  • Provider(s)/Educational Partner(s)

    Provided by

  • Accreditation and Designation Statement

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

    Instructions to Receive Credit
    To receive credit, read the introductory CME material, listen to the podcast, and complete the evaluation, attestation, and post-test, answering at least 100% of the post-test questions correctly.

    Release date: October 1, 2020
    Expiration date: September 30, 2021

  • Statement of Evidence-Based Content

    Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

    Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

  • Contact Information

    For CME questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866-858-7434 or email info@med-iq.com.

  • Disclaimer

    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Commercial Support

    This activity is supported by an educational grant from Pfizer. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Related
Comments
  • Overview

    Statment of Need
    Recent investigations into the underlying mechanisms of atopic dermatitis have revealed the importance of the JAK/STAT pathway and downstream cytokines in driving inflammatory response and AD pathogenesis and have informed the recent development of novel targeted agents. The recent and rapid emergence of new data on novel targeted treatments for moderate-to-severe AD creates a knowledge gap for dermatologists and allergists. As emerging targeted therapies have the potential to become available relatively quickly, dermatologists and allergists must be familiar with the practical considerations associated with using these agents so that they are prepared to integrate these agents into the management of patients with moderate-to-severe AD in a safe and appropriate manner. This activity will bridge the knowledge gap by providing expert perspective on the translation of these data into clinical practice to optimize patient outcomes.

  • Target Audience

    This activity is intended for dermatologists and allergy clinicians who are involved in the care and treatment of patients with moderate-to-severe AD.  

  • Learning Objectives

    Upon completion, participants should be able to: 

    • Evaluate the clinical relevance of recent trial data surrounding targeted therapies in development for the treatment of moderate-to-severe AD 
  • Faculty

    Lawrence F. Eichenfield, MD
    Professor of Dermatology and Pediatrics
    Vice Chair, Department of Dermatology
    University of California San Diego School of Medicine
    Chief, Pediatric and Adolescent Dermatology
    Rady Children's Hospital
    San Diego, CA 

    Linda Stein Gold, MD
    Director of Dermatology Clinical Research  
    Henry Ford Health System  
    Detroit, MI  
    Division Head of Dermatology  
    Henry Ford Health System  
    West Bloomfield, MI

  • Activity Planners

    Christie Avraamides, PhD
    Clinical Content Manager
    Med-IQ
    Baltimore, MD

    Samantha Gordon, MS
    Accreditation Manager
    Med-IQ
    Baltimore, MD

    Amy Sison
    Director of CME
    Med-IQ
    Baltimore, MD

  • Disclosure Policy and Statements

    Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.

    The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 

    Lawrence F. Eichenfield, MD 
    Consulting fees/advisory boards: Almirall, Asana, Cutanea, Dermavant, DS Biopharma, Forte, Galderma Laboratories, L.P., Glenmark, Incyte Corporation, LEO Pharma, Inc., Lilly USA, LLC, L'Oreal, MatriSys Bioscience, Medimetriks/Otsuka America Pharmaceutical, Inc., MorphoSys, Novan, Novartis Pharmaceuticals Corporation, Ortho Dermatologics/Valeant Pharmaceuticals International, Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme 

    Investigator: AbbVie Inc., LEO Pharma, Inc., Regeneron Pharmaceuticals, Inc., Sanofi Genzyme 

    Linda Stein Gold, MD  
    Consulting fees/advisory boards: AbbVie Inc., Arcutis Biotherapeutics, Incyte Corporation, LEO Pharma, Inc., Lilly USA, LLC, Pfizer, Inc. 

    Fees received for promotional/non-CME activities: Pfizer, Inc. 

    Contracted research: AbbVie Inc., Arcutis Biotherapeutics, Incyte Corporation, LEO Pharma, Inc., Lilly USA, LLC, Pfizer, Inc. 

    References to unlabeled/unapproved off-label drug uses or products are mentioned in this presentation.

    The peer reviewers and activity planners have no financial relationships to disclose.

  • Provider(s)/Educational Partner(s)

    Provided by

  • Accreditation and Designation Statement

    Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Med-IQ designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

    Instructions to Receive Credit
    To receive credit, read the introductory CME material, listen to the podcast, and complete the evaluation, attestation, and post-test, answering at least 100% of the post-test questions correctly.

    Release date: October 1, 2020
    Expiration date: September 30, 2021

  • Statement of Evidence-Based Content

    Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, Med-IQ has a policy to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.

    Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

  • Contact Information

    For CME questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866-858-7434 or email info@med-iq.com.

  • Disclaimer

    The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

  • Commercial Support

    This activity is supported by an educational grant from Pfizer. 

  • System Requirements

    Our site requires a computer, tablet or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/cable). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Internet Explorer, Microsoft Edge, Chrome, Firefox or Safari. Users accustomed to IE8, IE9 IE10 are advised to update their browsers for the best experience.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

LIVE ON REACHMD RADIOBack to live radio

Loading...

Programs 11/23/20